This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

This study has been completed.
Sponsor:
Collaborator:
Unilever R&D
Information provided by:
Wageningen University
ClinicalTrials.gov Identifier:
NCT00167869
First received: September 12, 2005
Last updated: May 23, 2008
Last verified: May 2008
  Purpose
Hypertension is an increasingly important medical and public health issue. Literature suggests that there may be a role for dairy foods in the prevention and treatment of hypertension. Recently, it has been suggested that several peptides in milk proteins could have blood pressure lowering properties. LACTOPRES is a randomised, double-blind parallel trial to assess the blood pressure effect of an increased intake of dairy peptides in humans.

Condition Intervention Phase
Hypertension Behavioral: dairy peptides Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

Further study details as provided by Wageningen University:

Primary Outcome Measures:
  • Blood pressure

Estimated Enrollment: 135
Study Start Date: June 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • systolic blood pressure >= 140 mmHg
  • BMI between 18 and 32 kg/m2
  • apparently healthy

Exclusion Criteria:

  • antihypertensive medication
  • medically prescribed or slimming diet
  • lactating, pregnant
  • irregular pulse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167869

Locations
Netherlands
Wageningen University, Division of Human Nutrition
Wageningen, Netherlands, 6700 EV
Sponsors and Collaborators
Wageningen University
Unilever R&D
Investigators
Principal Investigator: Frans J Kok, PhD Wageningen University - Division of Human Nutrition
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00167869     History of Changes
Other Study ID Numbers: METC-WU 04/04
Study First Received: September 12, 2005
Last Updated: May 23, 2008

Keywords provided by Wageningen University:
hypertension
blood pressure
dairy peptides
bioactive peptides
randomized controlled trial

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 23, 2017